Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor

US12319689B2 · kind B2 · utility

Assignee

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

• Fei Liu · Nanjing, CN
• Yanlong Liu · Shandong, CN
• Hongjiang Xu · Lianyungang, CN
• Xiquan Zhang · 安丰镇, CN
• Shanchun Wang · 安丰镇, CN
• Jianqing Zhang · Lianyungang, CN
• Weiwei Feng · Mountain View, US
• Bin Wang · Beijing, CN
• Jinan Wang · Lianyungang, CN
• Yubing Wang · Southborough, US
• Xujing Tang · Lianyungang, CN
• Quandeng Nie · Lianyungang, CN

Key dates

• Filing date: May 22, 2020
• Grant date: Jun 3, 2025
• Expiry date: Jul 17, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/496
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.